Compare · BRKR vs QTRX
BRKR vs QTRX
Side-by-side comparison of Bruker Corporation (BRKR) and Quanterix Corporation (QTRX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BRKR and QTRX operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- BRKR is the larger of the two at $9.02B, about 49.6x QTRX ($182.1M).
- Over the past year, BRKR is up 43.4% and QTRX is down 27.9% - BRKR leads by 71.3 points.
- QTRX has been more active in the news (11 items in the past 4 weeks vs 3 for BRKR).
- BRKR has more recent analyst coverage (22 ratings vs 13 for QTRX).
- Company
- Bruker Corporation
- Quanterix Corporation
- Price
- $58.22-1.79%
- $3.87-2.40%
- Market cap
- $9.02B
- $182.1M
- 1M return
- +4.37%
- +26.06%
- 1Y return
- +43.43%
- -27.87%
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- News (4w)
- 3
- 11
- Recent ratings
- 22
- 13
Bruker Corporation
Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through three segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. It offers life science tools based on magnetic resonance technology; life science mass spectrometry and ion mobility spectrometry solutions; analytical and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies; and radiological/nuclear detectors for chemical, biological, radiological, nuclear, and explosive detection. The company also provides X-ray instruments, atomic force microscopy instrumentation, fluorescence optical microscopy instruments, analytical tools for electron microscopes and X-ray metrology, defect-detection equipment for semiconductor process control, and spark optical emission spectroscopy systems, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments. In addition, it offers superconducting and non-superconducting materials and devices. The company serves academic and government research customers; pharmaceutical and biotechnology, diagnostics, chemical, food and beverage, clinical, nanotechnology, semiconductor, and other industrial companies; nonprofit laboratories; academic institutions and medical schools; contract research organizations; nonprofit and for-profit forensics, and environmental and clinical microbiology laboratories; agriculture, food, and beverage safety laboratories; hospitals and government departments; agencies; raw material manufacturers; and other businesses involved in materials analysis through direct sales forces, distributors, independent sales representatives, and other representatives. Bruker Corporation was incorporated in 1991 and is headquartered in Billerica, Massachusetts.
Quanterix Corporation
Quanterix Corporation, a life sciences company, develops and markets digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a sensitive automated multiplex protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection technology in various applications, including direct detection of nucleic acids. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assay kits and other consumables such as reagents. In addition, it offers contract research services, including sample testing, homebrew assay development, and custom development services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct sales force, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.
Latest BRKR
- EXEC VP&PRES BRUKER NANO INC. Munch Mark exercised 2,000 shares at a strike of $22.19 and sold $120,500 worth of shares (2,000 units at $60.25) as part of a pre-agreed trading plan (SEC Form 4)
- Bruker Expands Infection Detection Portfolio with Acquisition of Metagenomic mNGS DISQVER® Platform for Pathogenic Microorganisms in Blood
- New insider Pusch Wolfgang claimed ownership of 10,154 shares (SEC Form 3)
- EXEC VP&PRES BRUKER NANO INC. Munch Mark exercised 2,000 shares at a strike of $22.19 and sold $109,520 worth of shares (2,000 units at $54.76) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form S-3ASR filed by Bruker Corporation
- Bruker Showcases Expanding Microbiology & Infection Diagnostics Portfolio at ASM Microbe 2026
- Bruker Launches new timsMRMS Mass Spectrometry Platform for Unique Ultra-Complex Mixture Applications in the Energy Industry
- Wolfe Research resumed coverage on Bruker
- Bruker Announces Major Strides in 4D Proteomics Performance, Further Advances In Intact and Top-Down Functional Proteoform Analysis, and Innovations in Hybrid Qual/Quant 4D Metabolomics – all to Enable Deeper Insights into Disease Biology
- SEC Form SD filed by Bruker Corporation
Latest QTRX
- Chief Technology Officer Miller Michael Francis converted options into 1,558 shares and covered exercise/tax liability with 467 shares, increasing direct ownership by 3% to 36,068 units (SEC Form 4)
- SEC Form 4 filed by Chief Financial Officer Faessler Jason F.
- Quanterix Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Anthem Blue Cross and Blue Shield Establishes Commercial Coverage for LucentAD® Complete; Quanterix to Present New Data Highlighting Multi-Analyte Advantages
- Director Mendel Scott converted options into 8,073 shares, increasing direct ownership by 51% to 24,056 units (SEC Form 4)
- Director Lai Goldman Myla converted options into 8,073 shares, increasing direct ownership by 116% to 15,041 units (SEC Form 4)
- Director Mendel Scott was granted 3,456 shares, increasing direct ownership by 26% to 16,837 units (SEC Form 4)
- Director Donnelly William P was granted 5,472 shares, increasing direct ownership by 4% to 160,305 units (SEC Form 4)
- Chief Technology Officer Miller Michael Francis converted options into 130 shares and covered exercise/tax liability with 39 shares, increasing direct ownership by 0.26% to 34,977 units (SEC Form 4)
- Chief Financial Officer Sriram Vandana covered exercise/tax liability with 548 shares and converted options into 1,833 shares, increasing direct ownership by 4% to 31,283 units (SEC Form 4)